Prolactinoma

References

Key articles

Melmed S, Casanueva FF, Hoffman AR, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Full text  Abstract

Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994 Oct 6;331(14):904-9. Abstract

Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010 Jan;95(1):43-51.Full text  Abstract

Xia MY, Lou XH, Lin SJ, et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018 Jan;59(1):50-61. Abstract

Reference articles

1. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006 Aug;27(5):485-534.Full text  Abstract

2. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol. 1994 Sep;41(3):359-64. Abstract

3. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75. Abstract

4. Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990 Dec;71(6):1427-33. Abstract

5. Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011 Oct;165(4):509-15. Abstract

6. Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab. 2006 Sep;91(9):3316-23.Full text  Abstract

7. Cazabat L, Bouligand J, Salenave S, et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab. 2012 Apr;97(4):E663-70.Full text  Abstract

8. Cuny T, Pertuit M, Sahnoun-Fathallah M, et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. Eur J Endocrinol. 2013 Mar 15;168(4):533-41. Abstract

9. Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002 Feb;87(2):457-65.Full text  Abstract

10. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006 May 26;312(5777):1228-30. Abstract

11. Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest. 2002 Jan;109(2):277-83.Full text  Abstract

12. Melmed S, Casanueva FF, Hoffman AR, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Full text  Abstract

13. Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metabol. 2014 Feb;58(1):9-22.Full text  Abstract

14. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994 Oct 6;331(14):904-9. Abstract

15. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485-534.Full text  Abstract

16. Colao A, Abs R, Barcena DG, et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf). 2008 Jan;68(1):66-71. Abstract

17. Di Sarno A, Landi ML, Cappabianca P,et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001 Nov;86(11):5256-61.Full text  Abstract

18. De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves: meta-analysis of observational studies. Herz. 2013 Dec;38(8):868-80. Abstract

19. Valassi E, Klibanski A, Biller BM. Clinical review: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010 Mar;95(3):1025-33.Full text  Abstract

20. Drake WM, Stiles CE, Howlett TA, et al; UK Dopamine Agonist Valvulopathy Group. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014 Jan;99(1):90-6. Abstract

21. Gamble D, Fairley R, Harvey R, et al. Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review. Ther Adv Drug Saf. 2017 Jul;8(7):215-29.Full text  Abstract

22. Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010 Jan;95(1):43-51.Full text  Abstract

23. Xia MY, Lou XH, Lin SJ, et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018 Jan;59(1):50-61. Abstract

24. Barber TM, Kenkre J, Garnett C, et al. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol (Oxf). 2011 Dec;75(6):819-24. Abstract

25. Pan L, Zhang N, Wang EM, et al. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg. 2000 Dec;93(suppl 3):10-3. Abstract

26. Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf). 2010 Aug;73(2):236-42. Abstract

27. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr. 1987 Sep 1;65(17):823-7. Abstract

28. Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92.Full text  Abstract

29. Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85.Full text  Abstract

30. Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. Abstract

31. Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. 2007 Feb;156(2):225-31. Abstract

32. Albani A, Ferraù F, Angileri FF, et al. Multidisciplinary management of pituitary apoplexy. Int J Endocrinol. 2016 Dec 15;2016:7951536.Full text  Abstract

33. Baldeweg SE, Vanderpump M, Drake W, et al. Society For Endocrinology endocrine emergency guidance: emergency management of pituitary apoplexy in adult patients. Endocr Connect. 2016 Sep;5(5):G12-5.Full text  Abstract

34. Lubina A, Olchovsky D, Berezin M, et al. Management of pituitary apoplexy: clinical experience with 40 patients. Acta Neurochir (Wien). 2005 Feb;147(2):151-7. Abstract

35. Maccagnan P, Macedo CL, Kayath MJ, et al. Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab. 1995 Jul;80(7):2190-7. Abstract

36. Tirosh A, Shimon I. Management of macroprolactinomas. Clin Diabetes Endocrinol. 2015 Jul 20;1:5.Full text  Abstract

Use of this content is subject to our disclaimer